Boehringer Ingelheim announced that the US Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults.. Spesolimab, marketed in the US as Spevigo, is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signalling pathway within the immune system shown to be involved in the pathogenesis of GPP.
